Wake Forest University Health Sciences: Multiple Myeloma trials

The registry lists 22 Multiple Myeloma studies with Wake Forest University Health Sciences as lead sponsor. 5 are open to participants now and 8 have results posted.

Early Phase 1 1Phase 1 3Phase 2 9No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Neurocognitive Trajectories After BCMA CAR-TRecruitingNCT07740317
• Pre-malignant States to Hematologic Malignancies in FirefightersRecruitingNCT06870760
• CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot StudyRecruitingNCT06644625
• Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingNCT04822337Phase 1/2
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruitingNCT01890486
• Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma PatientsTerminatedNCT04770402Not applicableResults posted
• Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04113018Phase 2Results posted
• Precision Medicine for Patients With Identified Actionable MutationsTerminatedNCT04111107Phase 2Results posted
• Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple MyelomaTerminatedNCT03870451Not applicableResults posted
• LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaCompletedNCT03773107Phase 1/2Results posted
• LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple MyelomaCompletedNCT03361306Phase 2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseasesCompletedNCT00453206Not applicableResults posted
• Nivolumab in Multiple Myeloma Patients After Idecabtagene VicleucelActive, not recruitingNCT06523621Phase 2
• Study of Dara-Pembro for Multiple Myeloma PatientsWithdrawnNCT04361851Phase 2
• Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple MyelomaWithdrawnNCT04230031Phase 2
• Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT02971410Early Phase 1
• B-Cell Hematologic Malignancy Vaccination RegistryWithdrawnNCT02298816
• Study of the Immune Response After Vaccination in Multiple Myeloma PatientsCompletedNCT02294487
• Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
• Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
• Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other DiseasesCompletedNCT00376922Not applicable